Biosimilar Pricing and Competition: How Political Visibility Shapes Biologic Pricing after Loss of Exclusivity Introduction Biologics have reshaped the treatment landscape across a broad Read More »
Optimize your evidence plan How an early payer value narrative informed the evidence generation plan for an innovative therapy targeting a metabolic disease Read More
Optimize your evidence plan How a deep understanding of CDx pricing and reimbursement informed strategic R&D decision-making Read More
Optimize your evidence plan How creating a unified vision and comprehensive framework for Real-World Evidence (RWE) supported seamless execution of RWE projects Read More
Optimize your evidence plan How developing and testing of a value narrative with payers formed the foundation for a strong early market access strategy Read More
Optimize your evidence plan How synthesizing multiple perspectives has enabled the refinement of the clinical development plan and market access strategy for a novel drug in PD Read More
Optimize your evidence plan How synthesizing multiple perspectives has enabled the refinement of the market access strategy for four novel cell therapies Read More
